Kuros Biosciences' MagnetOs is a suitable alternative to autograft for spinal fusion when used as a standalone graft, according to an animal study in JOR Spine.
Here are five things to know:
1. Researchers implanted MagnetOs Granules and MagnetOs Putty into 25 adult female Merino sheep who underwent posterolateral spinal fusion at L2-3 and L4-5 levels with instrumentation.
2. The study authors assessed outcomes at six-, 12- and 26-weeks postoperatively. At 12-weeks postoperatively, researchers found 100 percent fusion rates in all treatment groups.
3. The three treatment groups showed a statistically significant decrease in lateral bending at the fusion levels at 12-weeks and 26-weeks compared to six-weeks postoperatively, which further confirmed spinal fusion success.
4. Histological assessment at 12-weeks postoperatively demonstrated a 75 percent fusion rate for autograft, 92 percent fusion rate for MagnetOs Granules and 83 percent fusion rate for MagnetOs Putty. Fusion rates further increased at 26-weeks post-implantation.
5. The researchers did not observe any significant differences in range of motion between the treatment groups at any time.